A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

[1] Kim K(2002)Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification Eur J Cancer 38 75-81

[2] Kim WS(1998)Peripheral T cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification Ann Oncol 9 849-55

[3] Jung CW(2014)Chemotherapeutic advancements in peripheral T-cell lymphoma Semin Hematol 51 17-24

[4] Im YH(2010)Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification Am J Hematol 85 760-4

[5] Kang WK(2012)Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01 J Clin Oncol 30 3093-9

[6] Lee MH(2011)Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study J Clin Oncol 29 1182-9

[7] Park CH(2012)Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy J Clin Oncol 30 631-6

[8] Ko YH(2012)Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study J Clin Oncol 30 2190-6

[9] Ree HJ(2015)Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the Pivotal Phase II BELIEF (CLN-19) Study J Clin Oncol 33 2492-9

[10] Park K(2014)Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma J Clin Oncol 32 1157-63

[1] Kim K(2002)Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification Eur J Cancer 38 75-81

[2] Kim WS(1998)Peripheral T cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification Ann Oncol 9 849-55

[3] Jung CW(2014)Chemotherapeutic advancements in peripheral T-cell lymphoma Semin Hematol 51 17-24

[4] Im YH(2010)Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification Am J Hematol 85 760-4

[5] Kang WK(2012)Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01 J Clin Oncol 30 3093-9

[6] Lee MH(2011)Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study J Clin Oncol 29 1182-9

[7] Park CH(2012)Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy J Clin Oncol 30 631-6

[8] Ko YH(2012)Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study J Clin Oncol 30 2190-6

[9] Ree HJ(2015)Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the Pivotal Phase II BELIEF (CLN-19) Study J Clin Oncol 33 2492-9

[10] Park K(2014)Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma J Clin Oncol 32 1157-63